About Synkrino Development Company (SDC)
Novel Biotech Financing
Low Risk - Attractive Returns
Drug Development Performance
SDC is a novel financing model for innovative early to mid-stage therapeutic assets
Drug Development Performance
Low Risk - Attractive Returns
Drug Development Performance
SDC actively designs and manages asset development to clinical and value inflection checkpoints
Low Risk - Attractive Returns
Low Risk - Attractive Returns
Low Risk - Attractive Returns
SDC is an orthogonal and risk reducing approach to investing in biotech across technology platforms, biological targets, TAs, and diseases
SDC | At a glance
6 | Therapeutic assets in initial portfolio
Drug candidates in our initial portfolio include potential treatments for diseases such as Osteo-Arthritis; Obesity, Diabetes and Cardiometabolic Diseases; Immuno-Resistant Tumors; NSCLC; Microvillous Inclusion Disease; and Systemic Sclerosis (SSc) and Lung Fibrosis.
15 | Additional assets in process
The programs we are currently progressing through our funnel include potential treatments for diseases such as Merkel cell carcinoma, non-small cell lung cancer, systemic juvenile idiopathic arthritis, systemic sclerosis, colon cancer, Parkinson's disease, vitiligo, etc.
41 | Pharma experts in SDC network
The combined experience of our team of scientific experts exceed 500 years of drug research and development - therapeutic areas of expertise include but are not limited to anti-retrovirals, auto-immune diseases, neurodegenerative diseases, oncology, cardio-metabolic diseases, etc.
100+ | Assets diligenced
During the last 2 years we have conducted both scientific and commercial diligence of well over 100 individual early-stage biotech programs
10 | Modalities in initial portfolio
The modalities of the initial SDC portfolio include gene therapy, mAbs, protein degraders, bicyclic peptides, macrocycles, GAG mimetic, mRNA, small molecules, etc.